11/30/2022

Pediatrix Therapeutics announced a collaboration agreement with Aclaris Therapeutics to acquire the development, production and commercialization rights to Aclaris’s JAK1/3 inhibitor ATI-1777 for all indications (including but not limited to atopic dermatitis) in Greater China.